14. Optional biopsies at baseline and as close as possible to first imaging restaging . 15. Where feasible, research blood for study assessments (see S ection 5) will be collected at baseline, 3 days and 1 week after the first M7824 + NHS -IL12 dose) as well as at weeks 3 and 7 and at restaging visits in selected participants , per PI discretion. 53 Abbreviated Title: Combo Immunotx in HPV Cancers Version Date: 05.12.2023 3.6 COST AND COMPENSATION 3.6.1 Costs NIH does not bill health insurance companies or participants for any research or related clinical care that participants receive at the NIH Clinical Center. If some tests and procedures are performed outside the NIH Clinical Center, participants may have to pay for these costs if they are not covered by an insurance company. Medicines that are not part of the study treatment will not be provided or paid for by the NIH Clinical Center. 3.6.2 Compensation There will be no compensation provided on this study. 3.6.3 Reimbursement The NCI will cover the costs of some expenses associated with protocol participation. Some of these costs may be paid directly by the NIH and some may be reimbursed to the participant/guardian as appropriat e. The amount and form of these payments are determined by the NCI Travel and Lodging Reimbursement Policy. 3.7 C RITERIA FOR REMOVAL FROM PROTOCOL THERAPY AND OFF STUDY CRITERIA Regardless of reason for removal from study therapy, participants will be asked to have a 28 day follow up safety visit. Participants who refuse to return for this visit will be asked to review any safety concerns by phone within this time period. 3.7.1 Criteria for R emoval f rom Protocol T herapy • Clinical or radiographic progression of disease except when the investigator feels the subject is still benefiting from treatment. (It is generally preferable for participants to remain on treatment past initial radiographic progression in case there is pseudo -progression, except when the investigator feels that the clinical picture warrants changing therapy at initial progression). • Unacceptable Toxicity possibly attributed to all active therapies . • Participant requests to be withdrawn from active therapy. • Start of another systemic anticancer treatment or participation in another investigational therapeutic trial. Focal palliative radiotherapy, ablation, or surgery to a site of disease will not necessitate removal from protocol therapy. • Investigator discretion .